RE: 2 Questions26 Aug 2022 12:34
Or the chances of it not being approved, it has passed 3 phases of clinical trails, their tech is being actively used in over a dozen hospitals and that the CRL last year was essentially only manufacturing queries. I'd be concerned and not invested if the FDA were querying specific aspects e.g. the gas exchange/length of time within the body, exit route of the gas or potential adverse reactions of the procedure. The results are impressive and it will add to the arsenal of diagnostic imaging options available to the clinicians that have the machine. The addition of another highly skilled and experienced individual today is a nice RNS today. Long covid is also still a ongoing problem for thousands with many individuals experiences different types of symptoms to another. If anyone had to put a % on it not being approved this time round surely it has to be under 10%. But all guesswork, people cautious after last years disappointment. Still plenty of time until the back end of September, expect this to rise further. Investors love a gamble. Good luck to us all.